glaxosmithkline plc-spon adr (GSK) Key Developments
GlaxoSmithKline To Sell Nicotinell Business
Mar 3 15
GlaxoSmithKline plc (LSE:GSK) intends to sell its Australian nicotine chewing gum business, Nicotinell, with indicative bids being expected before the end of March 2015. GlaxoSmithKline engaged Greenhill globally to sell several assets including the Nicotinell brand and smoking cessation products supplied in Australia under private-label arrangements.
GlaxoSmithKline plc Announces Board Changes
Feb 26 15
GlaxoSmithKline plc announced that Sir. Christopher Gent will step down as Chairman of GSK at the company's Annual General Meeting on 7 May 2015. He will be succeeded by Sir. Philip Hampton with effect from the end of the AGM. Si.r Philip joined GSK's Board as an independent Non-Executive Director on 1 January 2015, and will become Deputy Chairman on 1 April 2015. Sir. Philip chairs the company's Nominations Committee. He will remain Chairman of RBS until 31 August 2015. In addition, Tom de Swaan, independent Non Executive Director, is not seeking re-election to the Board at the AGM. He has been a Board member for 9 years and is currently Chairman of the Remuneration Committee and a member of the Audit & Risk Committee (of which he was previously Chairman), and the Nominations Committee. A successor for Mr. de Swaan as Chairman of the Remuneration Committee will be announced in due course. Jing Ulrich has decided not to stand for re-election to the Board at the AGM.
Insulet Corporation Announces Distribution Agreement with Glaxosmithkline
Feb 26 15
Insulet Corporation announced that following a four year distribution agreement with GlaxoSmithKline (GSK), the Company will assume full rights to distribute the OmniPod System in the Canadian market via a newly created Canadian Subsidiary, Insulet Canada Corporation. This will include all sales, marketing, training and support activities. The transfer is expected to be complete by end of June 2015. According to the Canadian Diabetes Association, there are approximately 3.3 million Canadians currently living with diabetes. 1 About 5% to 10% of people living with diabetes have type 1 diabetes, which is always treated with insulin. Insulet and GSK are working collaboratively to help ensure a seamless experience for all OmniPod users and healthcare providers during this transition, with the aim to keep all existing services intact.
GlaxoSmithKline plc Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-04-2015 08:30 AM
Feb 18 15
GlaxoSmithKline plc Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-04-2015 08:30 AM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Speakers: Stewart Kay, Director, Transactions.
GlaxoSmithKline plc Announces Executive Changes
Feb 17 15
GlaxoSmithKline plc announced Jack Bailey, currently senior vice president for policy, payers and vaccines, will take over the role of head of U.S. pharmaceutical operations effective immediately.